Human/Primate CXCL1/GRO alpha/KC/CINC-1 Alexa Fluor™ Plus 680-conjugated Antibody

The gene for CXCL1/GRO alpha was initially discovered in hamster cells, using subtractive hybridization techniques, as a message that is over-expressed in tumorigenic cells and in normal cells during growth stimulation. The hamster cDNA was cloned and used as a probe for the subsequent cloning of the human GRO cDNA. Independently, a cDNA encoding a secreted protein with melanoma growth stimulating activity (MGSA) was also cloned from a human melanoma cell line and found to be identical to GRO. In addition to the initially cloned GRO gene, now designated CXCL1, two additional GRO genes, GRO beta or MIP-2 alpha and GRO gamma or MIP‑2 beta, which shared 90% and 86% amino acid sequence homology, respectively, with CXCL1, have been identified. All three human GROs are members of the alpha (C-X-C) subfamily of chemokines.

The three GRO cDNAs encode 107 amino acid precursor proteins from which the N-terminal 34 amino acid residues are cleaved to generate the mature GROs. There are no potential N-linked glycosylation sites in the amino acid sequences. GRO expression is inducible by serum or PDGF and/or by a variety of inflammatory mediators, such as IL-1 and TNF, in monocytes, fibroblasts, melanocytes, and epithelial cells. In certain tumor cell lines, GRO is expressed constitutively.

Similar to other alpha chemokines, the three GRO proteins are potent neutrophil attractants and activators. In addition, these chemokines are also active toward basophils. All three GROs can bind with high affinity to the IL-8 receptor type B. It remains to be seen if a unique GRO receptor(s) also exist. The rat homolog of human CXCL1, CINC, is much more active than human CXCL1 on rat neutrophils, suggesting that this cytokine may have selective species specificity.